Daniela Wesch

Daniela Wesch

Kiel, SH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 70 publications

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

Journal: Journal for immunotherapy of cancer

Published: November 30, 2025

Novel L1CAM-antibody drug conjugates exert potent anti-tumor activity in preclinical models of even advanced pancreatic cancer.

Novel L1CAM-antibody drug conjugates exert potent anti-tumor activity in preclinical models of even advanced pancreatic cancer.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: November 21, 2025

Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from in vitro assays.

Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from in vitro assays.

Journal: Frontiers in immunology

Published: November 04, 2025

Correction: Tumor-restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer.

Correction: Tumor-restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer.

Journal: Frontiers in immunology

Published: July 23, 2025

Tumor-restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer.

Tumor-restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer.

Journal: Frontiers in immunology

Published: May 14, 2025

Function and Spatial Organization of Tumor-Invasive Human γδ T Cells-What Do We Know?

Function and Spatial Organization of Tumor-Invasive Human γδ T Cells-What Do We Know?

Journal: European journal of immunology

Published: July 02, 2024

Editorial: New insights into innate immune cell-based immunotherapies in cancer.

Editorial: New insights into innate immune cell-based immunotherapies in cancer.

Journal: Frontiers in immunology

Published: March 15, 2024

Vdelta1 T cells are more resistant than Vdelta2 T cells to the immunosuppressive properties of galectin-3.

Vdelta1 T cells are more resistant than Vdelta2 T cells to the immunosuppressive properties of galectin-3.

Journal: Frontiers in immunology

Published: August 30, 2023

Reprogramming of human γδ T cells by expression of an anti-CD19 TCR fusion construct (εTRuC) to enhance tumor killing.

Reprogramming of human γδ T cells by expression of an anti-CD19 TCR fusion construct (εTRuC) to enhance tumor killing.

Journal: Journal of leukocyte biology

Published: August 04, 2023

Selection of cross-reactive T cells by commensal and food-derived yeasts drives cytotoxic TH1 cell responses in Crohn's disease.

Selection of cross-reactive T cells by commensal and food-derived yeasts drives cytotoxic TH1 cell responses in Crohn's disease.

Journal: Nature medicine

Published: March 08, 2023

Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarcinoma.

Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarcinoma.

Journal: Frontiers in oncology

Published: February 07, 2023

Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.

Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.

Journal: Frontiers in immunology

Published: February 02, 2023

Showing 1-12 of 70

Last Updated: 09/26/2026